Arcus Biosciences (RCUS) Stock Price, News & Analysis

Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Key Stats

• Today's Range: $8.96 to $9.18
• 50-Day Range: $7.49 to $10.04
• 52-Week Range: $6.50 to $18.98
• Volume: 196,143 shs
• Average Volume: 875,467 shs
• Market Capitalization: $954.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.13
• Consensus Rating: Moderate Buy

Arcus Biosciences Stock Analysis - MarketRank™

Arcus Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 1287th out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcus Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.15) to ($4.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcus Biosciences is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcus Biosciences is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcus Biosciences has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.98% of the float of Arcus Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcus Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcus Biosciences has recently increased by 16.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcus Biosciences does not currently pay a dividend.

Dividend Growth

Arcus Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.98% of the float of Arcus Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcus Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcus Biosciences has recently increased by 16.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.75

News Sentiment

Arcus Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Arcus Biosciences this week, compared to 6 articles on an average week.

Search Interest

3 people have searched for RCUS on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcus Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Arcus Biosciences is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RCUS Stock Analysis - Frequently Asked Questions

How have RCUS shares performed this year?

Arcus Biosciences' stock was trading at $14.89 on January 1st, 2025. Since then, RCUS stock has decreased by 39.4% and is now trading at $9.0230.
View the best growth stocks for 2025 here.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.12. The business's quarterly revenue was down 80.7% compared to the same quarter last year.
Read the conference call transcript.

When did Arcus Biosciences IPO?

Arcus Biosciences (RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' top institutional investors include Gilead Sciences Inc. (29.68%), Vanguard Group Inc. (6.32%), Woodline Partners LP (4.84%) and Parkman Healthcare Partners LLC (1.15%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang, Yasunori Kaneko and Alexander Azoy.
View institutional ownership trends.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/17/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:RCUS
• CIK: 1724521
• Web: www.arcusbio.com
• Phone: (510) 694-6200
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.13
• High Stock Price Target: $44.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +165.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$307 million
• Net Margins: -102.66%
• Pretax Margin: -102.28%
• Return on Equity: -45.59%
• Return on Assets: -22.38%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 5.24
• Quick Ratio: 5.24

Sales & Book Value

• Annual Sales: $141 million
• Price / Sales: 6.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.17 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 105,885,000
• Free Float: 80,256,000
• Market Cap: $961.65 million
• Optionable: Optionable
• Beta: 0.83